research SnapshotDx Quiz: March 2016
JAK inhibitors may help treat alopecia areata by reversing hair loss.
Search
for
Sort by
Research
240-270 / 1000+ results research Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
The inhibitor affects androgen metabolism but not ovarian function.
research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Resolution of experimental malaria-associated acute respiratory distress syndrome is Alox12 independent and shows residual inflammation
Resolving malaria-related lung issues doesn't rely on Alox12 and leaves some inflammation.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research ALOPECIA AREATA: ASPECTOS FISIOLÓGICOS E AVANÇOS TERAPÊUTICOS – UMA REVISÃO DE LITERATURA
JAK inhibitors show promise for treating Alopecia Areata, but more research is needed for better, accessible treatments.
research 440 Squaric acid dibutylester, used in alopecia areata immunotherapy, promotes innate immune-driven hair growth with CD206+ macrophage accumulation in the dermis
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Vibration assisted analgesia during intralesional corticosteroid therapy for alopecia
Vibration assisted analgesia reduces pain during corticosteroid therapy for alopecia.
research Clinical and demographic factors associated with nail involvement in adult alopecia areata patients at Al-Kadhmia teaching hospital, Baghdad, 2023
Nail changes in alopecia areata are common and may indicate severity and genetic risk.
research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research LB1040 Machine learning-based predictive model with routine blood work identifies moderate-severe alopecia areata
Machine learning can use blood tests to help predict moderate-to-severe alopecia areata.
research Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women
Minoxidil works better for female hair loss than alfatradiol, both safe.
research ALLETHRIN INDUCED TOXICOPATHOLOGICAL ALTERATIONS IN ADULT MALE ALBINO RATS
Allethrin caused harmful effects and organ damage in rats, worsening with higher doses and longer exposure.
research Associations between ionomic profile and metabolic abnormalities in a murine model of sodium sulfide induced alopecia areata
Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.
research Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK /STAT inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.
research JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
research 085 Autoantigen screening in C3H/HeJ mouse model of alopecia areata revealed high antigenicity of melanocyte-associated antigen epitopes
Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.
research A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database
Alopecia areata in Dubai mostly affects men, often involves autoimmune disorders, and has high healthcare costs, especially for psychological issues.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
This review highlights the effectiveness of Janus kinase (JAK) inhibitors in treating alopecia areata (AA), an autoimmune condition causing hair loss. JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib have shown significant hair regrowth by blocking cytokine signaling pathways. Clinical trials such as BRAVE-AA1/2 and ALLEGRO-2a/2b/3 reported substantial improvements, with baricitinib achieving SALT scores ≤20 in up to 40.9% of patients. Tofacitinib and ruxolitinib, used off-label, also demonstrated promising results. However, AA recurrence is common after stopping treatment. While JAK inhibitors are promising, they require ongoing research to optimize treatment and manage potential adverse events.
research Alopecia Areata: A Complex Cytokine Driven Disease
Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.
research Three months extended-release microspheres prepared by multi-microchannel microfluidics in beagle dog models
A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
research Identification of SLC40A1, LCN2, CREB5, and SLC7A11 as ferroptosis-related biomarkers in alopecia areata through machine learning
Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.
research Allopregnanolone is required for prepulse inhibition deficits induced by D1 dopamine receptor activation
Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research Early postnatal neuroactive steroid manipulation differentially affects recognition memory and passive avoidance performance in male rats
Changing neuroactive steroids in baby male rats affects their memory and learning differently as they grow up.